William Blair Weighs in on Repligen Co.’s Q2 2023 Earnings (NASDAQ:RGEN)

Posted by on May 6th, 2023

Repligen Co. (NASDAQ:RGEN – Get Rating) – Investment analysts at William Blair dropped their Q2 2023 EPS estimates for Repligen in a research note issued to investors on Wednesday, May 3rd. William Blair analyst M. Larew now expects that the biotechnology company will post earnings of $0.45 per share for the quarter, down from their previous estimate of $0.61. The consensus estimate for Repligen’s current full-year earnings is $2.37 per share. William Blair also issued estimates for Repligen’s Q4 2023 earnings at $0.75 EPS and FY2024 earnings at $2.93 EPS.

Repligen (NASDAQ:RGEN – Get Rating) last posted its quarterly earnings data on Tuesday, May 2nd. The biotechnology company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.05. Repligen had a net margin of 21.58% and a return on equity of 9.14%. The business had revenue of $182.70 million during the quarter, compared to the consensus estimate of $181.43 million. During the same quarter in the prior year, the company posted $0.92 earnings per share. The company’s quarterly revenue was down 11.5% compared to the same quarter last year.

Several other research firms also recently issued reports on RGEN. StockNews.com assumed coverage on Repligen in a report on Thursday, March 16th. They set a “sell” rating on the stock. KeyCorp reduced their target price on Repligen from $260.00 to $240.00 and set an “overweight” rating for the company in a research report on Thursday, February 23rd. Benchmark reduced their target price on Repligen from $230.00 to $210.00 in a research report on Wednesday. SVB Leerink reduced their target price on Repligen from $230.00 to $200.00 and set an “outperform” rating for the company in a research report on Friday, January 6th. Finally, Craig Hallum cut their price objective on Repligen from $220.00 to $207.00 in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $208.56.

Repligen Trading Up 1.9 %

NASDAQ RGEN opened at $160.16 on Friday. The stock’s 50-day moving average price is $167.98 and its two-hundred day moving average price is $174.91. The company has a market cap of $8.92 billion, a PE ratio of 54.29, a PEG ratio of 2.88 and a beta of 1.08. Repligen has a 1 year low of $137.21 and a 1 year high of $262.26.

Hedge Funds Weigh In On Repligen

Institutional investors and hedge funds have recently modified their holdings of the business. Hanseatic Management Services Inc. bought a new stake in Repligen in the 3rd quarter valued at approximately $27,000. Fortis Capital Advisors LLC acquired a new position in shares of Repligen during the 4th quarter worth approximately $35,000. Whittier Trust Co. increased its holdings in shares of Repligen by 108.6% during the 1st quarter. Whittier Trust Co. now owns 242 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 126 shares during the last quarter. Allworth Financial LP grew its holdings in Repligen by 62.7% in the 4th quarter. Allworth Financial LP now owns 262 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 101 shares in the last quarter. Finally, Achmea Investment Management B.V. acquired a new position in Repligen in the 4th quarter valued at $49,000. 91.00% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

(Get Rating)

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G.

Read More

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.